Apeloa Pharmaceutical Co

Apeloa Pharmaceutical Co Book Value per Share

The Book Value per Share of Apeloa Pharmaceutical Co (000739.SZ) as of Oct 22, 2026 is 5.45 CNY. In the previous year, Book Value per Share was 5.80 CNY — a change of -5.99% (lower).

Book Value per Share

5.45CNY

YoY

-5.99%

Last updated:

Book Value per Share of Apeloa Pharmaceutical Co is 2025 5.45 CNY. Book Value per Share of Apeloa Pharmaceutical Co was 2024 5.80 CNY. It decreases by -5.99% lower compared to the previous year.

The Apeloa Pharmaceutical Co Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2018
2.88 CNY
Jan 1, 2019
3.24 CNY
Jan 1, 2020
3.77 CNY
Jan 1, 2021
4.35 CNY
Jan 1, 2022
4.74 CNY
Jan 1, 2023
5.35 CNY
Jan 1, 2024
5.80 CNY
Jan 1, 2025
5.45 CNY
The Apeloa Pharmaceutical Co Book Value per Share history
YEARBook Value per ShareYoY
5.45CNY-5.99%
5.80CNY+8.34%
5.35CNY+12.90%
4.74CNY+8.93%
4.35CNY+15.24%
3.77CNY+16.53%
3.24CNY+12.64%
2.88CNY+9.68%
2.62CNY+16.57%
2.25CNY+8.27%
2.08CNY+4.80%
1.98CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Apeloa Pharmaceutical Co Stock analysis

What does Apeloa Pharmaceutical Co do? Apeloa Pharmaceutical Co., Ltd. generates revenue through the research, development, and production of active pharmaceutical ingredient (API) intermediates, contract development and production services (CDMO), and preparations. The company’s main products include bulk drugs, intermediates, chemical preparations, and Chinese traditional medicine preparations such as ubenimex capsules, cefixime, and amantadine. These products are sold to both domestic and overseas markets, with the company distributing its offerings across these segments. The firm’s business model focuses on serving pharmaceutical manufacturers and healthcare providers through its comprehensive range of API intermediates and finished preparations. The company’s revenue streams are derived from the sale of bulk drugs, intermediates, and chemical preparations, alongside its Chinese traditional medicine preparations like ubenimex capsules and cefixime. These products are targeted at pharmaceutical manufacturers seeking API intermediates and finished drug formulations. Apeloa Pharmaceutical serves both domestic and international clients, with its products distributed in both markets. The company’s CDMO services further support clients in the development and production of pharmaceutical products. Apeloa Pharmaceutical’s core business involves the production and sale of API intermediates, bulk drugs, and various preparations, including traditional Chinese medicine products. The company’s main customers are pharmaceutical manufacturers and healthcare providers who require intermediates for drug manufacturing and finished preparations for market distribution. Its domestic and overseas market presence ensures a diversified revenue base, with products like ubenimex capsules and amantadine contributing to its product portfolio. Apeloa Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Apeloa Pharmaceutical Co stock

Book Value per Share of Apeloa Pharmaceutical Co is 5.45 CNY in 2025.

Book Value per Share of Apeloa Pharmaceutical Co changed from 5.80 CNY to 5.45 CNY, representing a -5.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share Apeloa Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Apeloa Pharmaceutical Co

All Key Metrics — Apeloa Pharmaceutical Co